Vytorin - Merck.com
... Active liver disease or unexplained persistent elevations in hepatic transaminase levels [see Warnings and Precautions (5.2)]. Women who are pregnant or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essen ...
... Active liver disease or unexplained persistent elevations in hepatic transaminase levels [see Warnings and Precautions (5.2)]. Women who are pregnant or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essen ...
Product Monograph Template - Standard
... hemarthrosis, in patients with hemophilia type A and B treated with protease inhibitors (PIs). In some patients additional factor VIII was given. In more than half of the reported cases, treatment with PIs was continued or reintroduced. A causal relationship between PI therapy and these events has n ...
... hemarthrosis, in patients with hemophilia type A and B treated with protease inhibitors (PIs). In some patients additional factor VIII was given. In more than half of the reported cases, treatment with PIs was continued or reintroduced. A causal relationship between PI therapy and these events has n ...
medicine - Deutsches Ärzteblatt
... CI: Severe renal impairment. The use of brinzolamide in patients with severely reduced renal function (creatinine clearance <30 mL/ min) or patients with hyperchloremic acidosis has not been investigated. Since brinzolamide and its main metabolite are excreted through the kidneys, its use in such pa ...
... CI: Severe renal impairment. The use of brinzolamide in patients with severely reduced renal function (creatinine clearance <30 mL/ min) or patients with hyperchloremic acidosis has not been investigated. Since brinzolamide and its main metabolite are excreted through the kidneys, its use in such pa ...
Prescribing Information as of XXXX ALLEGRA (fexofenadine hydrochloride)
... The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg, twice daily, in normal volunteers. Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively. Because ...
... The mean elimination half-life of fexofenadine was 14.4 hours following administration of 60 mg, twice daily, in normal volunteers. Human mass balance studies documented a recovery of approximately 80% and 11% of the [14C] fexofenadine hydrochloride dose in the feces and urine, respectively. Because ...
Hydroxyzine Dihydrochloride
... of normal subjects. The half-life was increased to 37 hours and the serum concentrations of the carboxylic metabolite, cetirizine, were higher than in young patients with a normal liver function. Daily dose or dose frequency should be reduced in patients with impaired liver function (see Section Dos ...
... of normal subjects. The half-life was increased to 37 hours and the serum concentrations of the carboxylic metabolite, cetirizine, were higher than in young patients with a normal liver function. Daily dose or dose frequency should be reduced in patients with impaired liver function (see Section Dos ...
Keppra, INN-Levetiracetam
... electrophysiological properties of rat hippocampal CA3 neurons in vitro, but, at 10 µM, it produced a two-fold reduction of the increase in firing induced either by NMDA or by bicuculline. Levetiracetam had no effect on glutamate decarboxylase and GABA transaminase in vitro. Using 3H-levetiracetam, ...
... electrophysiological properties of rat hippocampal CA3 neurons in vitro, but, at 10 µM, it produced a two-fold reduction of the increase in firing induced either by NMDA or by bicuculline. Levetiracetam had no effect on glutamate decarboxylase and GABA transaminase in vitro. Using 3H-levetiracetam, ...
pediatric handbook
... Synergy with beta-lactams for severe S. aureus and Enterococcus infections: 3mg/kg/day IV ÷ q8h *gentamicin on long- Doses as high as 10mg/kg/DAY IV q24h recommended in patients with cystic fibrosis. term back-order until Spring 2016-use (Inhaled tobramycin for CF patients): 80mg bid to tid via inha ...
... Synergy with beta-lactams for severe S. aureus and Enterococcus infections: 3mg/kg/day IV ÷ q8h *gentamicin on long- Doses as high as 10mg/kg/DAY IV q24h recommended in patients with cystic fibrosis. term back-order until Spring 2016-use (Inhaled tobramycin for CF patients): 80mg bid to tid via inha ...
How Do Atrial-Selective Drugs Differ From Antiarrhythmic
... Current pharmacologic strategies for the management of atrial fibrillation (AF) include use of 1) sodium channel blockers, which are contraindicated in patients with coronary artery or structural heart disease because of their potent effect to slow conduction in the ventricles, 2) potassium channel ...
... Current pharmacologic strategies for the management of atrial fibrillation (AF) include use of 1) sodium channel blockers, which are contraindicated in patients with coronary artery or structural heart disease because of their potent effect to slow conduction in the ventricles, 2) potassium channel ...
diltiazem hydrochloride injection
... WARNINGS). High intravenous dosages (4.5 mg/kg tid) administered to dogs resulted in significant bradycardia and alterations in AV conduction. In subacute and chronic dog and rat studies designed to produce toxicity, high oral doses of diltiazem were associated with hepatic damage. In special subacu ...
... WARNINGS). High intravenous dosages (4.5 mg/kg tid) administered to dogs resulted in significant bradycardia and alterations in AV conduction. In subacute and chronic dog and rat studies designed to produce toxicity, high oral doses of diltiazem were associated with hepatic damage. In special subacu ...
Nuedexta Prescribing Information
... NUEDEXTA causes dose-dependent QTc prolongation [see Clinical Pharmacology (12.2)]. QT prolongation can cause torsades de pointes-type ventricular tachycardia, with the risk increasing as the degree of prolongation increases. When initiating NUEDEXTA in patients at risk of QT prolongation and torsad ...
... NUEDEXTA causes dose-dependent QTc prolongation [see Clinical Pharmacology (12.2)]. QT prolongation can cause torsades de pointes-type ventricular tachycardia, with the risk increasing as the degree of prolongation increases. When initiating NUEDEXTA in patients at risk of QT prolongation and torsad ...
Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function
... By virtue of its ability to inhibit platelet aggregation, aspirin prolongs the bleeding time in many normal individuals, and the effect is dose-dependent. Although it is not a consistent finding, a paradoxically greater bleeding time prolongation has occurred with lower doses. 61 -63 This may be bec ...
... By virtue of its ability to inhibit platelet aggregation, aspirin prolongs the bleeding time in many normal individuals, and the effect is dose-dependent. Although it is not a consistent finding, a paradoxically greater bleeding time prolongation has occurred with lower doses. 61 -63 This may be bec ...
MEDICATION GUIDE ZEGERID® (ze ger id) (omeprazole / sodium
... platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as omeprazole, that interfere with CYP2C19 activity. Concomitant use of clopidogrel with 80 mg omeprazole redu ...
... platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as omeprazole, that interfere with CYP2C19 activity. Concomitant use of clopidogrel with 80 mg omeprazole redu ...
Lecture 8 (One compartment IV model for renal clearance
... the amount excreted in the urine after infinite time (Ae0-) would equal the dose. … that an Excretion Rate vs. Time plot had a slope proportional to K …that an Excretion rate vs. mid point plasma concentration had a slope equal to Renal clearance (ClR). But now, moxi has other routes of elimination ...
... the amount excreted in the urine after infinite time (Ae0-) would equal the dose. … that an Excretion Rate vs. Time plot had a slope proportional to K …that an Excretion rate vs. mid point plasma concentration had a slope equal to Renal clearance (ClR). But now, moxi has other routes of elimination ...
Suprax (cefixime)
... Once daily dosing only must be used for urinary tract infections, since twice daily dosing was shown to be not as effective in clinical studies. Do not use SUPRAX to treat Staphylococcus aureus as this strain of staphylococcus is resistant to cefixime. Renal Impairment: SUPRAX should be used with pa ...
... Once daily dosing only must be used for urinary tract infections, since twice daily dosing was shown to be not as effective in clinical studies. Do not use SUPRAX to treat Staphylococcus aureus as this strain of staphylococcus is resistant to cefixime. Renal Impairment: SUPRAX should be used with pa ...
Indocin Injection
... in neonates treated with INDOCIN I.V. were no greater than in placebo controls and were statistically significantly lower than in surgically-treated neonates. The following additional adverse reactions in neonates have been reported from the collaborative study, anecdotal case reports, from other st ...
... in neonates treated with INDOCIN I.V. were no greater than in placebo controls and were statistically significantly lower than in surgically-treated neonates. The following additional adverse reactions in neonates have been reported from the collaborative study, anecdotal case reports, from other st ...
RM-0106.02
... sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be ca ...
... sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be ca ...
TOPAMAX® - Janssen
... The tablet and capsule formulations of TOPAMAX are bioequivalent at equivalent doses. The pharmacokinetic profile of topiramate compared to other antiepileptic drugs shows a long plasma elimination half-life, linear pharmacokinetics, predominantly renal clearance, absence of significant protein bind ...
... The tablet and capsule formulations of TOPAMAX are bioequivalent at equivalent doses. The pharmacokinetic profile of topiramate compared to other antiepileptic drugs shows a long plasma elimination half-life, linear pharmacokinetics, predominantly renal clearance, absence of significant protein bind ...
PRODUCT MONOGRAPH Pr PERIDEX ORAL RINSE
... Chemical Name: 1,1’-hexamethylene bis [5- (p-chlorophenyl) biguanide] di-D-gluconate Structure: ...
... Chemical Name: 1,1’-hexamethylene bis [5- (p-chlorophenyl) biguanide] di-D-gluconate Structure: ...
(Dosing, switching, and other practical information).
... Use with caution in patients with renal insufficiency. Amisulpride is renally eliminated, and in patients with renal insufficiency, systemic clearance is reduced by a factor of 2.5 to 3. The AUC in mild renal failure is increased two-fold and almost tenfold in moderate renal failure. Although there ...
... Use with caution in patients with renal insufficiency. Amisulpride is renally eliminated, and in patients with renal insufficiency, systemic clearance is reduced by a factor of 2.5 to 3. The AUC in mild renal failure is increased two-fold and almost tenfold in moderate renal failure. Although there ...
lustral - Pharmaline
... with caution. A lower or less frequent dose should be used in patients with hepatic impairment. Use in Patients with Impairment of Renal Function Sertraline is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. In studies of patients with mild to moderate ...
... with caution. A lower or less frequent dose should be used in patients with hepatic impairment. Use in Patients with Impairment of Renal Function Sertraline is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. In studies of patients with mild to moderate ...
Plavix - Sanofi Canada
... hemolytic anemia, neurological findings, renal dysfunction, and fever. Acquired haemophilia has been reported following use of clopidogrel, manifesting as a marked increase in bleeding or bruising. In cases of confirmed isolated activated partial thromboplastin time (aPTT) prolongation with or witho ...
... hemolytic anemia, neurological findings, renal dysfunction, and fever. Acquired haemophilia has been reported following use of clopidogrel, manifesting as a marked increase in bleeding or bruising. In cases of confirmed isolated activated partial thromboplastin time (aPTT) prolongation with or witho ...
a new antiarrhythmic compound potent class iii
... arrhythmia encountered in clinical practice, and has multiple causes, such as coronary artery disease, heart failure, valve disease and hypertension. Patients with AF have an increased risk of death from stroke due to embolisation of atrial thrombi which form because the rapid and irregular activati ...
... arrhythmia encountered in clinical practice, and has multiple causes, such as coronary artery disease, heart failure, valve disease and hypertension. Patients with AF have an increased risk of death from stroke due to embolisation of atrial thrombi which form because the rapid and irregular activati ...
Cardiovascular Active Medications
... • Elevation of plasma glucose & lactate. • Extravasation cause necrosis ...
... • Elevation of plasma glucose & lactate. • Extravasation cause necrosis ...
Performance Measures 2016 Clinical Measures for Adults
... continuity of care for these patients by addressing the multiple settings where patients receive ...
... continuity of care for these patients by addressing the multiple settings where patients receive ...
Part I: Summary of Product Information
... 5 and 6 HCV infection is very limited. Interferon-free therapy for genotype 1, 4, 5 and 6 HCV infection Interferon-free regimens for patients with genotype 1, 4, 5 and 6 HCV infections with Gratisovir have not been investigated in phase 3 studies. The optimal regimen and treatment duration have not ...
... 5 and 6 HCV infection is very limited. Interferon-free therapy for genotype 1, 4, 5 and 6 HCV infection Interferon-free regimens for patients with genotype 1, 4, 5 and 6 HCV infections with Gratisovir have not been investigated in phase 3 studies. The optimal regimen and treatment duration have not ...
Discovery and development of direct thrombin inhibitors
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a more safer anticoagulant.